| Issue |
Title |
File |
| Vol 20, No 3 (2025) |
Молекулярный фенотип диффузной В-клеточной крупноклеточной лимфомы как основа персонифицированного подхода к лечению пожилых пациентов |
|
|
.
|
| Vol 21, No 1 (2026) |
What’s the price for the best? Pharmacoeconomic comparison of asciminib and imatinib in first line of chronic myelogenous leukemia treatment |
(Rus)
|
|
Shuvaev V.A., Zakharov S.G., Turkina A.G., Martynkevich I.S., Chelysheva E.Y., Shukhov O.A., Mitina T.A., Falaleeva N.A.
|
| Vol 18, No 1 (2023) |
Comparative clinical and economic evaluation of polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin and prednisolone (R-CHP) in the 1st line therapy for adult patients with diffuse large B-cell lymphoma |
(Rus)
|
|
Dyakov I.N.
|
| Vol 17, No 4 (2022) |
Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity |
(Rus)
|
|
Kasimova A.R., Kolbin A.S., Proskurin M.A., Balykina Y.E.
|
| Vol 17, No 3 (2022) |
Comparative clinical and economic assessment of polatuzumab vedotin therapy in combination with bendamustine and rituximab for adult transplantation-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma |
(Rus)
|
|
Dyakov I.N., Bushkova K.K.
|
| Vol 15, No 4 (2020) |
Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma |
(Rus)
|
|
Avxentyev N.A., Pazuhina E.M., Tumyan G.S., Zeynalova P.A.
|
| Vol 15, No 1 (2020) |
Pharmacoeconomic aspects of recurrent / refractory chronic lymphocytic leukemia treatment |
(Rus)
|
|
Rudakova A.V., Stadnik E.A.
|
| Vol 14, No 4 (2019) |
Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers |
(Rus)
|
|
Fitilev S.B., Vozzhaev A.V., Shkrebneva I.I., Kudlay D.A., Gapchenko E.V., Markova O.A., Borоzinets A.Y., Kazarov A.A., Pantyushenko М.S.
|
| Vol 11, No 3 (2016) |
Proteasome inhibitors: situation and prospects (literature review and own data) |
(Rus)
|
|
Rukavitsyn A.A., Rukavitsyn O.A.
|
| Vol 9, No 3 (2014) |
Role of biosimilars in neutropenia prevention in cancer patients |
|
|
Ptushkin V.V.
|
| Vol 9, No 3 (2014) |
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy |
(Rus)
|
|
Kuter D.J., Bussel J.B., Newland A., Baker R.I., Lyons R.M., Wasser J., Viallard J., Macik G., Rummel M., Nie K., Jun S.
|
| Vol 9, No 2 (2014) |
Colistine pharmacokinetics and Colistimethate sodium daily dose calculation in children with chemotherapy induced neutropenia |
(Rus)
|
|
Zakharevich V.I., Dmitriev V.V.
|
| Vol 9, No 1 (2014) |
Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review |
(Rus)
|
|
Dmitrieva N.V., Petukhova I.N.
|
| Vol 9, No 1 (2014) |
Clinical experience with romiplostim |
(Rus)
|
|
Kuchma G.B., Kozlova L.K., Kuznetsova Y.Y., Borisyuk S.B.
|
| Vol 8, No 3 (2013) |
Clinical and biochemical features of some intravenous iron complexes |
(Rus)
|
|
Abashin S.Y., Misyurina E.N., Zhelnova E.I., Misyurin A.V.
|
| Vol 8, No 2 (2013) |
Adverse events of modern antifungal drugs during treatment of invasive fungal infections |
(Rus)
|
|
Dmitrieva N.V., Petukhova I.N.
|
| Vol 8, No 2 (2013) |
Immune thrombocytopenia: clinical manifestation and therapy response. The interim analysis of Russian register of patients with primary immune thrombocytopenia and literature review |
(Rus)
|
|
Lisukov I.A., Maschan A.A., Shamardina A.V., Chagorova T.V., Davydkin I.L., Sycheva T.M., Zagoskina T.P., Karyagina E.V., Salogub G.N., Savinova M.T., Shelekhova T.V., Kovaleva L.G., Shneyder T.V., Unzhekova A.N., Kuznetsova E.E., Shatokhin Y.V., Ivanova M.O., Vinogradova E.Y., Volodicheva E.M., Markova I.V., Kanyukova O.V., Abdulkadyrov K.M., Sedlova Y.A., Osyunikhina S.M., Kaplanov K.D., Tsvetaeva N.V., Akhmadeev A.R., Uspenskaya O.S., Kulagin A.D., Medvedeva N.V., Rumyantsev A.G., Afanasiev B.V.
|
| Vol 8, No 2 (2013) |
Influence of low molecular weight heparin on cancer patients’ survival |
(Rus)
|
|
Ptushkin V.V.
|
| Vol 8, No 2 (2013) |
Anemia in cancer patients: current treatment options (review) |
(Rus)
|
|
Chernov V.M., Ptushkin V.V.
|
| Vol 8, No 1 (2013) |
Modern concepts of biosimilars in hematology and oncology |
(Rus)
|
|
Ptushkin V.V.
|
| Vol 6, No 1 (2011) |
Treatment of patients with refractory immune thrombocytopenia: literature review and case report |
(Rus)
|
|
Ptushkin V.V., Minenko S.V., Biyachuev E.R., Pshonkin A.V., Shubina A.V.
|
| No 3 (2010) |
Bendamustine: a new view on treatment of chronic lymphocytic leukemia |
(Rus)
|
|
Nikitin Y.A.
|
| No 3 (2010) |
Osteodestruction markers and quality of life parameters at pomegara (pamidronate) treatment in multiple myeloma patients with lytic bone lesions |
(Rus)
|
|
Lunin V.V., Yurova Y.V., Kudryavtseva O.A., Minenko S.V., Ptushkin V.V.
|
| No 4 (2009) |
Tasigna advantage in treatment of newly diagnosed chronic myeloid leukemia: results of «Novartis research» |
(Rus)
|
|
Editorial a.
|
| No 2 (2009) |
Immediate side effects study of locally manufactured filgrastim («Leucostim®») in neutropenia treatment and prophylactics in children |
(Rus)
|
|
Shipovskaya N.Y., Samochatova E.V., Polushkina O.B., Maschan M.A., Kalinina I.I., Gracianskay A.N., Kostileva M.N., Maschan A.A.
|
| No 1 (2009) |
Stimulation of platelet production: the new treatment approach to chronic immune thrombocytopenic purpura |
(Rus)
|
|
Maschan A.A., Rumyantsev A.G.
|
| No 4 (2008) |
Clinical efficacy of dacogen in myelodysplastic syndrome |
(Rus)
|
|
Golenkov A.K., Dudina G.A., Buravtsova I.V., Kataeva E.V., Oparina N.V.
|
| 1 - 27 of 27 Items |
|
